Reading this on a mobile device? Try our optimized mobile version here:

November 14, 2012
Sign upForwardArchive
News for the PBM Industry

  Featured Story 
  • FDA, state regulators seek tighter oversight of drug compounders
    The FDA and state health regulators called for congressional action to bolster federal oversight of drug compounders as Congress prepared for hearings on a meningitis outbreak tied to the New England Compounding Center. "It is clear that the patchwork of disparate state regulations is not enough to keep the public safe," Massachusetts Department of Public Health interim Commissioner Dr. Lauren Smith wrote in prepared testimony filed with a House oversight panel. "FDA's authority over compounding pharmacies is more limited by law and needs to be strengthened," the FDA said. FDA Commissioner Dr. Margaret Hamburg is set to testify today. Reuters (11/13) LinkedInFacebookTwitterEmail this Story
  Legislative & Regulatory News 
  • Senator: GAO report shows need for price negotiation
    The prices of more than half of Part B drugs, which Medicare beneficiaries receive in clinical settings, could be negotiated if laws were changed, according to the Government Accountability Office. A GAO report found that Medicare paid $19.5 billion for Part B drugs in 2010. "This report helps show how expensive these drugs are and the huge potential for savings that could be realized by allowing the government to negotiate the price of Part B drugs," Sen. Herb Kohl, D-Wis., said. He has sponsored a bill to allow CMS to negotiate when Medicare accounts for more than half of the market for a drug. Modern Healthcare (subscription required) (11/13) LinkedInFacebookTwitterEmail this Story
  Drug Industry Spotlight 
  • Mistrust impedes global treaty on counterfeit drugs
    An objection from Indian officials effectively blocked nongovernmental experts from attending a World Health Organization meeting on counterfeit drugs. Leading health professionals and academics are pushing for an international law to keep counterfeit and substandard drugs off the market, but some officials in developing countries say multinational drugmakers have co-opted the movement in an effort to suppress generic competition. Reuters (11/13) LinkedInFacebookTwitterEmail this Story
The best way to find out if you can trust somebody is to trust them."
--Ernest Hemingway,
American author and journalist


Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information